Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TMBR

Timber Pharmaceuticals (TMBR)

Timber Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:TMBR
DateTimeSourceHeadlineSymbolCompany
29/11/202309:21GlobeNewswire Inc.Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE AmericanAMEX:TMBRTimber Pharmaceuticals Inc
19/09/202306:05GlobeNewswire Inc.Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceAMEX:TMBRTimber Pharmaceuticals Inc
21/08/202322:00GlobeNewswire Inc.Timber Pharmaceuticals to be Acquired by LEO PharmaAMEX:TMBRTimber Pharmaceuticals Inc
04/07/202306:05GlobeNewswire Inc.Timber Pharmaceuticals Discloses Communication From NYSE AmericanAMEX:TMBRTimber Pharmaceuticals Inc
20/06/202322:00GlobeNewswire Inc.Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital IchthyosisAMEX:TMBRTimber Pharmaceuticals Inc
05/06/202322:00GlobeNewswire Inc.Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001AMEX:TMBRTimber Pharmaceuticals Inc
16/05/202306:15GlobeNewswire Inc.Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial ResultsAMEX:TMBRTimber Pharmaceuticals Inc
01/04/202307:28GlobeNewswire Inc.Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial ResultsAMEX:TMBRTimber Pharmaceuticals Inc
20/03/202323:00GlobeNewswire Inc.Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental DermatologyAMEX:TMBRTimber Pharmaceuticals Inc
25/02/202300:00GlobeNewswire Inc.Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive IchthyosisAMEX:TMBRTimber Pharmaceuticals Inc
15/12/202200:30GlobeNewswire Inc.Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward OutlookAMEX:TMBRTimber Pharmaceuticals Inc
10/12/202208:05GlobeNewswire Inc.Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsAMEX:TMBRTimber Pharmaceuticals Inc
15/11/202200:00GlobeNewswire Inc.Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial ResultsAMEX:TMBRTimber Pharmaceuticals Inc
10/11/202200:20Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
09/11/202208:38Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
09/11/202204:09GlobeNewswire Inc.Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock SplitAMEX:TMBRTimber Pharmaceuticals Inc
03/11/202223:42Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
03/11/202223:22GlobeNewswire Inc.Timber Pharmaceuticals Announces Halt of Common Stock Trading  AMEX:TMBRTimber Pharmaceuticals Inc
26/10/202223:40TipRanksAnalysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR)AMEX:TMBRTimber Pharmaceuticals Inc
25/10/202223:31Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
25/10/202223:00GlobeNewswire Inc.Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive IchthyosisAMEX:TMBRTimber Pharmaceuticals Inc
04/10/202207:16Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
04/10/202201:56Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)AMEX:TMBRTimber Pharmaceuticals Inc
04/10/202200:00GlobeNewswire Inc.Timber Pharmaceuticals Announces $1.3 Million Registered Direct OfferingAMEX:TMBRTimber Pharmaceuticals Inc
14/09/202222:00GlobeNewswire Inc.Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital IchthyosisAMEX:TMBRTimber Pharmaceuticals Inc
13/09/202206:43Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
03/09/202206:17Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
30/08/202206:17Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
30/08/202206:05GlobeNewswire Inc.Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing DeficiencyAMEX:TMBRTimber Pharmaceuticals Inc
29/08/202222:00GlobeNewswire Inc.Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV CongressAMEX:TMBRTimber Pharmaceuticals Inc
 Showing the most relevant articles for your search:AMEX:TMBR